Layer3.news

AI by layer3.news

Filtering by: Vamil Divan · clear filter

THE TOP 5 ANALYST QUESTIONS FROM ABBVIE’S Q3 EARNINGS CALL

https://s.yimg.com/ny/api/res/1.2/kHOxyMj_cOakofKhZcoUPg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/stockstory_922/621a415265c388bc8e9eb8ecaf0fb0a8

✍️ AbbVie's third quarter results showed strong revenue growth, driven by immunology and neuroscience portfolios, but the market reacted negatively due to a sharp drop in operating margin and headwinds in the aesthetics segment.

👉 Revenue growth driven by immunology and neuroscience portfolios 👉 Sales growth from Skyrizi and Rinvoq 👉 Double-digit expansion in neuroscience products 👉 Sharp drop in operating margin 👉 Headwinds in the aesthetics segment

-- #RobMichael #TerenceFlynn #ChristopherSchott #VamilDivan #DavidAmsellem #GeoffreyMeacham #RoopalThakkar #JeffreyStewart #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqc7gtg2gyjq9umj4lwj0n2lkdz2e6nlsvsdtfcy5ycz2yv7cxzv0s07pa9f

Rob Michael Terence Flynn Christopher Schott Vamil Divan David Amsellem Geoffrey Meacham Roopal Thakkar Jeffrey Stewart

11/8/2025

npub1vap2usg…grwc3n

GUGGENHEIM REMAINS BULLISH ON PFIZER (PFE)

https://s.yimg.com/ny/api/res/1.2/EpAz_Vcy0hmyqhi5PSK_ZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487

✍️ Pfizer Inc. (NYSE:PFE) is a top drug stock to buy, with positive results from a Phase 3 clinical trial and a Buy rating from Guggenheim.

👉 Pfizer Inc. (NYSE:PFE) reported positive results from a Phase 3 clinical trial 👉 The vaccine's safety profile was consistent with previous studies 👉 No new safety concerns were identified 👉 Guggenheim maintained a Buy rating on Pfizer Inc. (NYSE:PFE) with a price target of $33.00

-- #VamilDivan #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqymy0nc2yvlx8fg73zmc8njgpshwmps23ydvwfy7trxz2udt76pvsuhkkwn

Vamil Divan business mainstream:perspective

9/18/2025

npub1vap2usg…grwc3n

WHAT DO ANALYSTS THINK ABOUT AMGEN INC. (AMGN)?

https://s.yimg.com/ny/api/res/1.2/Umivb7Omy8VqKH22zTmY9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/51e557354b24b248245adac46ac0da45

✍️ Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that reported a 9% increase in total revenues and a 92% rise in GAAP earnings per share in its fiscal Q2 2025 earnings.

👉 Amgen Inc. (NASDAQ:AMGN) reported a 9% increase in total revenues to $9.2 billion in its fiscal Q2 2025 earnings. 👉 GAAP earnings per share rose 92% to $2.65. 👉 Analysts have maintained a Hold rating on the stock. 👉 The company has a median price target of $276.39.

-- #VamilDivan #RaymondJames #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqv38vyzv9yk3tpr7d969juumh3p86z4d748hpf5d5glrjgqptcf5sxsnn8c

Vamil Divan Raymond James business mainstream:perspective

9/18/2025

npub1vap2usg…grwc3n

GUGGENHEIM MAINTAINS A HOLD ON AMGEN INC. (AMGN)

https://s.yimg.com/ny/api/res/1.2/Umivb7Omy8VqKH22zTmY9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/51e557354b24b248245adac46ac0da45

✍️ Amgen Inc. is a biotechnology company that discovers, develops, and markets human therapeutics, and is considered a cheap stock to buy for beginners.

👉 Amgen Inc. is a biotechnology company that discovers, develops, and markets human therapeutics 👉 The company reported its fiscal Q2 2025 earnings, with total revenues increasing 9% to $9.2 billion 👉 GAAP earnings per share (EPS) rose 92% to $2.65 👉 The company is considered a cheap stock to buy for beginners

-- #VamilDivan #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqc6tcaqufy6cgewskygarehr87kv6dwy5m9ggfztwz64dflvclh6qme60jv

Vamil Divan business mainstream:perspective

9/14/2025

npub1vap2usg…grwc3n

WHY ABBVIE STOCK FLEW HIGHER ON FRIDAY

https://s.yimg.com/ny/api/res/1.2/CsO2orrcpepCceF4kZiMrA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/76447e3a737185a46dc863afa966cc5d

✍️ Analysts raised their price targets on AbbVie, a pharmaceutical company, following its strong second-quarter results.

👉 Analysts raised their price targets on AbbVie following its strong second-quarter results 👉 The company's shares closed 3% higher after the price target increases 👉 Analysts cited the company's strong performance in the second quarter as a reason for the price target increases 👉 The company's growth in sales of certain blockbuster drugs, such as Skyrizi, was highlighted as a key factor in the price target increases

-- #TerranceFlynn #GaryNachman #VamilDivan #EricVolkman #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqlp8vzknamzrkc39jkn5c3kvhacc9y04q58eejx58m2cmqu2lptqszzqyrd

Terrance Flynn Gary Nachman Vamil Divan Eric Volkman business mainstream:perspective

8/3/2025

npub1vap2usg…grwc3n

ABBVIE SOARS ON SKYRIZI AND RINVOQ STRENGTH, OUTPACING HUMIRA EROSION

https://media.zenfs.com/en/Benzinga/2303db6939766b1e16b5cb7185782b8e

✍️ AbbVie Inc. reported strong second-quarter 2025 sales, beating consensus estimates, driven by the strength of its Skyrizi and Rinvoq products.

👉 AbbVie reported strong second-quarter 2025 sales of $15.42 billion, beating consensus estimates. 👉 The company's adjusted earnings increased 12.1% year over year, missing the consensus estimate. 👉 Skyrizi and Rinvoq products drove the growth, with the company raising its fiscal 2025 adjusted earnings guidance. 👉 Analysts are optimistic about the company's outlook, with Guggenheim Partners and Morgan Stanley maintaining their Buy ratings and raising their price forecasts.

-- #VamilDivan #Trump #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqywe87ll0t4y4g663sh34au6umcf9l4dxatnkt7d7ccnfwmv5dhwsw4t6tp

Vamil Divan Trump business mainstream:perspective

8/3/2025

npub1vap2usg…grwc3n

JOHNSON & JOHNSON STOCK: ANALYST ESTIMATES & RATINGS

https://s.yimg.com/ny/api/res/1.2/0Hwce52mzPentb466njf4Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/barchart_com_477/bc531ab7885d2cf67671138eedb42811

✍️ Johnson & Johnson, a healthcare giant, has outperformed the broader market despite lagging behind in the past year. The company's diversified business model and strong product portfolio have driven its stock price up 13.9% year-to-date.

👉 Johnson & Johnson operates through pharmaceuticals, medical devices, and consumer products divisions 👉 The company has outperformed the broader market in 2025 👉 The company's stock price has gained 13.9% year-to-date 👉 The company's strong product portfolio has driven its stock price up 6.2% in a single trading session 👉 Analysts expect an 8.8% year-over-year growth in adjusted EPS to $10.86 for the full fiscal 2025

-- #VamilDivan #NewBrunswick,NewJersey #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqve90ecdl586l86grlmy75pl98vmxrszuzpgm59x8xjpuhj0ngs8s7e4m76

Vamil Divan New Brunswick, New Jersey business mainstream:perspective

8/2/2025

npub1vap2usg…grwc3n

GUGGENHEIM MAINTAINED A HOLD RATING ON JOHNSON & JOHNSON (JNJ)

https://s.yimg.com/ny/api/res/1.2/DBFyZ0OZ_JyFkP8R8eQoiQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2

✍️ Guggenheim analyst Vamil Divan maintains a Hold rating on Johnson & Johnson with a price target of $164, citing concerns about tariff risks.

👉 Guggenheim analyst Vamil Divan maintains a Hold rating on Johnson & Johnson 👉 Price target of $164 👉 Concerns about tariff risks, particularly a potential 200% tariff on Pharmaceuticals by President Trump 👉 Q1 2025 results showed strong growth in the US market 👉 Struggling international market

-- #VamilDivan #PresidentTrump #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqzw2ztcc79s4pq855l0mqrsf6gq9f430m6yeg39gkwmy0e9lv82xs7nt7h2

Vamil Divan President Trump business mainstream:perspective

7/19/2025

npub1vap2usg…grwc3n

IS ABBVIE INC. (ABBV) THE BEST PHARMA STOCK TO INVEST IN AMID THE DOMESTIC MANUFACTURING BOOM?

https://s.yimg.com/ny/api/res/1.2/m1YYSOl9HO_x0LHuYGlC8Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee

✍️ President Trump signs an executive order to incentivize pharmaceutical companies to build domestic manufacturing capacity, streamlining the process and reducing tariffs on imported medicines.

👉 President Trump signs an executive order to incentivize pharmaceutical companies to build domestic manufacturing capacity 👉 The order streamlines the process for pharmaceutical companies to build new production sites in the US 👉 The order reduces tariffs on imported medicines 👉 The order increases inspections of foreign manufacturing plants

-- #PresidentTrump #MartyMakary #VamilDivan #UnitedStates #Europe #Germany #Ireland #Switzerland #health

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpq6vdaqemqg5mxerqr2z5ygfn6yphu5yaxu2d34zfug9q4xau4w40sk79x00

President Trump Marty Makary Vamil Divan United States Europe Germany Ireland Switzerland

5/15/2025

npub1vap2usg…grwc3n

WHY ABBVIE INC. (ABBV) IS AMONG THE BEST STOCKS THAT WILL ALWAYS GROW

https://s.yimg.com/ny/api/res/1.2/m1YYSOl9HO_x0LHuYGlC8Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee

✍️ The article discusses the potential risks of a recession in the US and the impact on the stock market, specifically focusing on AbbVie Inc. (NYSE:ABBV) and its potential for growth.

👉 The US economy is at risk of recession due to Trump's tariffs and macroeconomic uncertainty 👉 CFOs are pessimistic about the economy's prospects 👉 AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company with two blockbuster drugs 👉 The company is poised for growth due to its ability to increase dividends and its two top-selling drugs